Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Gregory C. Ravizzini Image

      Gregory C. Ravizzini

      Department of Nuclear Medicine, Division of Diagnostic Imaging

      Present Title & Affiliation

      Primary Appointment

      Professor, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Professor, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

      Research Interests

      Ongoing Research Support

      No Assigned # 09/01/2012-08/31/2014

      GE Healthcare

      [

      18F]GEH121224 Positron Emission Tomography (PET) post treatment evaluation in xenografts with HER2

      expression

      Role: PI

      The major goals of this project are to evaluate the uptake and distribution of the novel radiotracer [

      18F]

      GEH121224 following the administration of anti-HER2 therapeutics in nude mice bearing HER2-postitive tumor

      xenografts

      Completed Research Support

      None

      Education & Training

      Postgraduate Training

      2008-2011Clinical Residency, Diagnostic Radiology, SUNY Upstate Medical University, Syracuse, New York
      2007-2008Research Fellowship, Molecular Imaging, National Cancer Institute-National Institutes of Health, Bethesda, Maryland
      2004-2006Clinical Fellowship, Nuclear Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
      2002-2004Clinical Residency, Nuclear Medicine, Emory University, Atlanta, Georgia
      2001-2002Clinical Internship, Internal Medicine, East Carolina University, Greenville, North Carolina
      1998-2001Research Associate, Nuclear Cardiology, Duke University, Durham, North Carolina
      1991-1998Medical Training, Doctor of Medicine, Fluminense Federal University, Rio de Janeiro

      Licenses & Certifications

      2014Texas Controlled Substances (DPS)
      2012Controlled Substances (DEA)
      2011American Board of Radiology
      2008Texas Medical Board
      2006New York Medical Physician
      2006American Board of Nuclear Medicine

      Experience & Service

      Faculty Academic Appointments

      Associate Professor, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023

      Assistant Professor, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017

      Administrative Appointments/Responsibilities

      Medical Director ad interim, Center for Advanced Biomedical Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2020

      Other Professional Positions

      Medical Staff, Department of Nuclear Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, 2007 - 2008

      Extramural Institutional Committee Activities

      Member, PET/CT Steering Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2019

      Member, DI Faculty Functional Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present

      Member, Hyperpolarizer Operational Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2020

      Member, CABI Executive Steering Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2020

      Member, DI Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2018

      Member, PET/MRI Organization Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2015

      Member, DI Research Functional Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2015

      Member, PET/CT QA & Education Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

      Member, Nuclear Medicine Research Peer Review Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present

      Honors & Awards

      2007 - 2008Clinical Research Training Award (CRTA), National Cancer Institute
      2004J. Randolph Perry Scholarship Fund, Southeastern Chapter of the Society of Nuclear Medicine

      Professional Memberships

      Society of Nuclear Medicine and Molecular Imaging

      2011 - Present

      Harris County Medical Society

      2011 - Present

      Radiological Society of North America

      2001 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2018. AvidinOX + 177Lu-biotin: A new Pre-targeting Paradigm. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      2. 2012. Artifacts in PET/CT Imaging. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.

      National Presentations

      1. 2016. Quantitative Assessment of New Regularized Time-of-Flight (R-TOF) or QClear by GE, and Conventional Time-of-Flight (TOF) and Non-TOF PET Reconstructions in an Oncologic Patient Population. Invited. Radiological Society of North America (RSNA) 2016 Annual Meeting. Chicago, IL, US.
      2. 2016. Quantitative Assessment of Normal Adrenal Gland Metabolic Activity Using Time-of-Flight (TOF) with Resolution Recovery versus Non-TOF PET Reconstructions. Invited. Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2016 Annual Meeting. San Diego, CA, US.
      3. 2016. PET Pitfalls are the Pits: False-Positives Encountered in Abdominal 18F-FDG PET-CT. Invited. Society of Abdominal Radiology (SAR) 2016 Annual Meeting. Waikoloa, HI, US.
      4. 2009. PET Imaging of Prostate Cancer. Invited. National Cancer Institute. Bethesda, MD, US.
      5. 2008. Combined Use of T-2 Weighted and Diffusion-Weighted MRI for Detection of Prostate Cancer. Conference. 8th Annual Fellows & Young Investigators Colloquium, Center for Cancer Research, National Cancer Institute. Ocean City, MD, US.

      International Presentations

      1. 2016. Alpha particle radium-223 dichloride (223RaCl2 ) in high risk osteosarcoma. Invited. American Society of Clinical Oncology (ASCO) 2016 Annual Meeting. Chicago, US.
      2. 2016. A First-in-Human Radioimmunotherapy Trial of FF-21101, Dosimetry of a Novel Radiolabeled Monoclonal Antibody Targeting P-cdaherin. Invited. 2016 Worldwide Innovative Networking (WIN) in Personalized Cancer Medicine Symposium. Paris, FR.
      3. 2008. Minimizing Inflow Effect in Measured AIF for Prostate DCE-MRI. Conference. ISMRM 16th Scientific Meeting & Exhibition. Toronto, CA.
      4. 1997. Spiral Computed Tomography in the Evaluation of the Abdominal Aorta Aneurysm. Conference. 27th Jornada Paulista de Radiologia. Sao Paulo, BR.
      5. 1997. Spiral Computed Tomography in the Evaluation of the Kidneys. Conference. 27th Jornada Paulista de Radiologia. Sao Paulo, BR.

      Formal Peers

      1. 2009. Nuclear Molecular Imaging. Invited. Syracuse, NY, US.
      2. 2007. Principles of PET/CT in Cancer. Visiting. Cape Town, ZA.
      3. 2007. Principles of PET/CT in Cancer. Visiting. Cape Town, ZA.
      4. 2007. Principles of PET/CT in Cancer. Visiting. Cape Town, ZA.
      Read More
      Less

      Grant & Contract Support

      Date: 2025 - 2030
      Title:Targeted Suppression of Microtubule Dynamics for Treatment of Metastatic Castration-Resistant Prostate Cancer
      Funding Source:UT Health/NIH
      Role:Co-PI
      ID:R01CA298343
      Date: 2016 - 2017
      Title:Target Radionuclide Therapy of Pancreatic Cancer
      Funding Source:NIH/SBIR
      Role:Consult
      ID:N43CO-2016-00018
      Date: 2014 - 2014
      Title:Dosimetry of the Novel Radiotracer 111In-FF21101 in Non-Human Primates
      Funding Source:Boston Strategics
      Role:PI

      Selected Publications

      Peer-Reviewed Articles

      1. Tang, C, Sadiq, M, Ravizzini, G, Salem, AE. Current Applications of Molecular Imaging in Adrenal Imaging. Magnetic resonance imaging clinics of North America 33(4):595-612, 2025. e-Pub 2025.
      2. Fang AM, Chapin BF, Shi CW, Sun J, Qayyum A, Kundra V, Corn PG, Kuban DA, Ravizzini GC, Surasi DSS, Ma J, Bathala T. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer. Prostate Cancer Prostatic Dis 28(3):761-766, 2025. e-Pub 2025. PMID: 39289537.
      3. Gonzalez, F, Ravizzini, G, Santiago, G, Chasen, B, Hussein, A. Comparison of Three Therapeutic Radiopharmaceutical Infusion Methods for Single and Multivial Applications. Journal of nuclear medicine technology 53(3):187-192, 2025. e-Pub 2025. PMID: 40796234.
      4. Martiniova, L, Kamel, S, Kairemo, K, Benjamin, RS, Somaiah, N, Ravizzini, G, Nassif, EF. Predictive Value of Quantitative Parameters of 18F-FDG PET/CT in Patients with Liposarcoma. Diagnostics 14(18), 2024. e-Pub 2024. PMID: 39335700.
      5. Kuo, PH, Esposito, G, Ulaner, G, Yoo, DC, Zukotynski, KA, Ravizzini, G, Penny, R, Miller, MP, Chau, A, Davis, P, Chapin, BF, Schuster, DM. Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer. Journal of Nuclear Medicine 65(8):1239-1243, 2024. e-Pub 2024. PMID: 38871390.
      6. Virarkar, M, Gruschkus, SK, Ravizzini, G, Vulasala, SR, Javadi, S, Bhosale, PR. Assessing the effectiveness of MRI, 18F-fluciclovine PET, SUVmax, and PSA in detecting local recurrence of prostate cancer after prostatectomy. Polish Journal of Radiology 89:e196-e203, 2024. e-Pub 2024. PMID: 38783912.
      7. Ravizzini, PI, Lino, HA, Ravizzini, G, Toledo, Ld. Percutaneous radiofrequency ablation of an actively bleeding renal angiomyolipoma. Einstein (Sao Paulo, Brazil) 22:eRC1008, 2024. e-Pub 2024. PMID: 39699407.
      8. Awiwi, M, Gjoni, M, Vikram, R, Altinmakas, E, Doğan, H, Bathala, TK, Naik, SA, Ravizzini, G, Kandemirli, SG, Elsayes, KM, Salem, UI. MRI and PSMA PET/CT of Biochemical Recurrence of Prostate Cancer. Radiographics 43(12), 2023. e-Pub 2023. PMID: 37999983.
      9. Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF, Group LS. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). Eur Urol 84(4):361-370, 2023. e-Pub 2023. PMID: 37414702.
      10. Ravizzini G, Erwin W, De Palatis L, Martiniova L, Subbiah V, Paolillo V, Mitchell J, McCoy AP, Gonzalez J, Mawlawi O. Dosimetry of a Novel 111Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human Primates. Cancers (Basel) 15(18), 2023. e-Pub 2023. PMID: 37760501.
      11. Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM. Reply by Authors. J Urol 210(2):310-311, 2023. e-Pub 2023. PMID: 37416959.
      12. Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM, Group SS. Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). J Urol 210(2):299-311, 2023. e-Pub 2023. PMID: 37126069.
      13. Martiniova, L, Zielinski, RJ, Lin, M, Depalatis, L, Ravizzini, G. The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment. Cancer Journal (United States) 28(6):446-453, 2022. e-Pub 2022. PMID: 36383907.
      14. Wong FC, Martiniova L, Masrani A, Ravizzini GC. 18F-Fluciclovine-Avid Reactive Axillary Lymph Nodes After COVID-19 Vaccination. Clin Nucl Med 47(2):154-155, 2022. e-Pub 2021. PMID: 34183501.
      15. Surasi DSS, Lin L, Ravizzini G, Wong F. Supraclavicular and Axillary Lymphadenopathy Induced by COVID-19 Vaccination on 18F-Fluorthanatrace, 68Ga-DOTATATE, and 18F-Fluciclovine PET/CT. Clin Nucl Med 47(2):195-196, 2022. e-Pub 2022. PMID: 34507331.
      16. Teyateeti, A, Mahvash, A, Long, J, Abdelsalam, M, Avritscher,R, Kaseb, A, Odisio,B, Ravizzini GC, Surasi,D, Teyateeti,A, Macapinlac, H, Cheenu Kappadath, S. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 27(47):8166-8181. e-Pub 2021. PMID: 35068861.
      17. Kairemo, K, Roszik, J, Anderson,P, Ravizzini GC, Rao, A, Macapinlac, HA, Subbiah, V. 18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases 45(5). e-Pub 2021. PMID: 34706830.
      18. Lin M, Paolillo V, Le DB, Macapinlac H, Ravizzini GC. Monoclonal antibody based radiopharmaceuticals for imaging and therapy. Curr Probl Cancer:100796. e-Pub 2021. PMID: 34657748.
      19. Baiomy A, Schellingerhout D, Chapin BF, Weinberg JS, Raza SM, Macapinlac H, Ravizzini G. Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer. Nucl Med Commun 42(7):755-762, 2021. e-Pub 2021. PMID: 33741867.
      20. Baiomy A, Martiniova L, Efstathiou E, Schuster DM, Ravizzini G. Prostate Cancer Liver Metastases Presenting as Relatively Photopenic Lesions on 18F-Fluciclovine PET/CT. Clin Nucl Med 46(4):e240-e241, 2021. e-Pub 2021. PMID: 33208612.
      21. Baiomy A, Jensen CT, Ward JF, Chasen BA, Ravizzini GC. Incidental 18F-Fluciclovine Uptake in a Desmoid Tumor Detected in a Patient Undergoing PET/CT Imaging for Prostate Cancer. Clin Nucl Med 46(4):355-357, 2021. e-Pub 2021. PMID: 33323736.
      22. Lin M, Ta RT, Kairemo K, Le DB, Ravizzini GC. Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives. Cancer Biother Radiopharm 36(3):237-251, 2021. e-Pub 2021. PMID: 32589458.
      23. Bitar R, Szklaruk J, Martiniova L, Zurita AJ, Chery LJ, Ravizzini G. 18F-Fluciclovine Uptake in a Ureterocele. Clin Nucl Med 46(1):e3-e5, 2021. e-Pub 2021. PMID: 32956112.
      24. Teyateeti A, Teyateeti A, Ravizzini GC, Xu G, Tang C, Tu SM, Macapinlac HA, Lu Y. Diagnostic performance of (18)F-fluciclovine PET/CT in prostate cancer patients with rising PSA level
      25. Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac H, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res 26(22):5830-5842, 2020. e-Pub 2020. PMID: 32816889.
      26. Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?. AJR Am J Roentgenol 214(6):1248-1258, 2020. e-Pub 2020. PMID: 32130049.
      27. Surasi DSS, Chapin B, Tang C, Ravizzini G, Bathala TK. Imaging and Management of Prostate Cancer. Semin Ultrasound CT MR 41(2):207-221, 2020. e-Pub 2020. PMID: 32446432.
      28. Lin M, Paolillo V, Ta RT, Damasco J, Rojo RD, Carl JC, Melancon MP, Ravizzini GC, Le DB, Santos EB. Fully automated preparation of 68Ga-PSMA-11?at?curie level quantity using cyclotron-produced 68Ga for clinical applications. Appl Radiat Isot 155:108936, 2020. e-Pub 2020. PMID: 31655351.
      29. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clin Cancer Res. e-Pub 2019. PMID: 30733229.
      30. Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open 4(1):e000439, 2019. e-Pub 2019. PMID: 30962954.
      31. Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis 21(1):4-21, 2018. e-Pub 2018. PMID: 29230009.
      32. Chism CB, Ravizzini GC, Macapinlac HA, Pan T. Quantitative comparison between regularized time-of-flight and OSEM PET reconstructions for small 18F-FDG-avid lesions. Nucl Med Commun 38(6):529-536, 2017. e-Pub 2017. PMID: 28383318.
      33. Kairemo K, Ravizzini GC, Macapinlac HA, Subbiah V. An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma. Diagnostics (Basel) 7(2), 2017. e-Pub 2017. PMID: 28375169.
      34. Chism CB, Somcio R, Chasen BA, Ravizzini GC. Increased 18F-FDG Uptake Associated With Gastric Banding Surgical Mesh on PET/CT. Clin Nucl Med 41(5):410-1, 2016. e-Pub 2016. PMID: 26825203.
      35. Martiniova L, Palatis LD, Etchebehere E, Ravizzini G. Gallium-68 in Medical Imaging. Current Radiopharmaceuticals 9:2-21, 2016. e-Pub 2016.
      36. Martiniova L, Palatis LD, Etchebehere E, Ravizzini GC. Gallium-68 in Medical Imaging. Curr Radiopharm 9(3):187 - 207, 2016. e-Pub 2016. PMID: 27804868.
      37. Turkbey B, Ravizzini G, Karcaaltincaba M. Imaging of Bladder Cancer: Update on Current Approaches for Diagnosis. Journal Belge de Radiologie-Belgisch Tijdschrift voor Radiologie (JBR-BTR) 94(4):178-84, 2011. e-Pub 2011. PMID: 21980733.
      38. Meirelles GS, Schöder H, Ravizzini GC, Gönen M, Fox JJ, Humm J, Morris MJ, Scher HI, Larson SM. Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer. Clin Cancer Res 16(24):6093-9, 2010. e-Pub 2010. PMID: 20975102.
      39. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, Khurana K, Ravizzini G, Albert PS, Merino MJ, Choyke PL. Prostate Cancer: Value of Multiparametric MR Imaging at 3 T for Detection--Histopathologic Correlation. Radiology 255(1):89-99, 2010. e-Pub 2010. PMID: 20308447.
      40. Ravizzini G, Turkbey B, Barrett T, Kobayashi H, Choyke PL. Nanoparticles in Sentinel Lymph Node Mapping. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1(6):610-23, 2009. e-Pub 2009. PMID: 20049820.
      41. Thakral C, Thomas L, Gajra A, Hutchison RE, Ravizzini GC, Vajpayee N. Plasmablastic Lymphoma in an Immunocompetent Patient. J Clin Oncol 27(25):e78-81, 2009. e-Pub 2009. PMID: 19581534.
      42. Kelloff GJ, Choyke P, Coffey DS, Scher HI, Wheeler TM, Anderson L, Tatum J, Scardino PT, Harisinghani M, Catalona WJ, Eisenberger MA, Hussain MH, Larson SM, Marberger M, Moul JW, Padhani A, Schnall MD, Sullivan DC, Wahl RL, Menard C, Clarke L, Cohen JK, Dahut WL, Dicker AP, Ellis RJ, Feleppa EJ, Farahani K, Frenkel V, Getzenberg RH, Gumbs-Petty B, Halpern EJ, Higley HR, Hruszkewycz AM, Jacobs P, Jessup JM, Kattan MW, Katz AE, Koch MO, Koutcher JA, Kurdziel KA, Kurhanewicz J, Lucia MS, Parnes HL, Petrick N, Pomper MG, Ravizzini G, Shankar LK, Sheinfeld A, Sigman CC, Smith MR, Speight JL, Steele V, Tang Y, Tempany C, Valicenti RK. Challenges in Clinical Prostate Cancer: Role of Imaging. AJR Am J Roentgenol 192(6):1455-70, 2009. e-Pub 2009. PMID: 19457806.
      43. Ravizzini G, Turkbey B, Kurdziel K, Choyke PL. New Horizons in Prostate Cancer Imaging. Eur J Radiol 70(2):212-26, 2009. e-Pub 2009. PMID: 18993004.
      44. Barrett T, Ravizzini G, Choyke PL, Kobayashi H. Dendrimers in Medical Nanotechnology. IEEE Eng Med Biol Mag 28(1):12-22, 2009. e-Pub 2009. PMID: 19150767.
      45. Ravizzini G, Meirelles GS, Horwitz SM, Grewal RK. 18F-FDG Uptake in Subcutaneous Panniculitis-like T-cell Lymphoma. Clin Nucl Med 33(12):903-5, 2008. e-Pub 2008. PMID: 19033805.
      46. Kurdziel KA, Ravizzini G, Croft B, Tatum J, Choyke P, Kobayashi H. The Evolving Role of Nuclear Molecular Imaging in Cancer. Expert Opin Med Diagn 2(7):829-842, 2008. e-Pub 2008. PMID: 19122861.
      47. Koyama Y, Barrett T, Hama Y, Ravizzini G, Choyke PL, Kobayashi H. In Vivo Molecular Imaging to Diagnose and Subtype Tumors Through Receptor-Targeted Optically Labeled Monoclonal Antibodies. Neoplasia 9(12):1021-9, 2007. e-Pub 2007. PMID: 18084609.
      48. Barrett T, Koyama Y, Hama Y, Ravizzini G, Shin IS, Jang BS, Paik CH, Urano Y, Choyke PL, Kobayashi H. In Vivo Diagnosis of Epidermal Growth Factor Receptor Expression Using Molecular Imaging with a Cocktail of Optically Labeled Monoclonal Antibodies. Clin Cancer Res 13(22 Pt 1):6639-48, 2007. e-Pub 2007. PMID: 17982120.
      49. Ravizzini G, Pryma DA, Meirelles GS, Divgi CR. I-123 MIBG Scan of Metastatic Neuroblastoma Mimicking a Bone Scan. Clin Nucl Med 31(9):558-60, 2006. e-Pub 2006. PMID: 16921285.
      50. Meirelles GS, Ravizzini G, Moreira AL, Akhurst T. Primary Pulmonary Meningioma Manifesting as a Solitary Pulmonary Nodule with a False-positive PET Scan. J Thorac Imaging 21(3):225-7, 2006. e-Pub 2006. PMID: 16915069.
      51. Meirelles GS, Ravizzini G, Yeung HW, Akhurst T. Esophageal Leiomyoma: A Rare Cause of False-Positive FDG Scans. Clin Nucl Med 31(6):342-4, 2006. e-Pub 2006. PMID: 16714896.
      52. Pryma DA, Ravizzini G, Amar D, Richards VL, Patel JB, Strauss HW. Cardiovascular Risk Assessment in Cancer Patients Undergoing Major Surgery. J Nucl Cardiol 12(2):151-7, 2005. e-Pub 2005. PMID: 15812368.
      53. Ravizzini G, Nguyen M, Schuster DM, Halkar RK. Central Line Injection Artifact Simulating Paratracheal on FDG PET Imaging. Clin Nucl Med 29(11):735-7, 2004. e-Pub 2004. PMID: 15483495.
      54. Ravizzini GC, Hanson MW, Shaw LK, Wong TZ, Hagge RJ, Pagnanelli RA, Jain D, Jr LH, Coleman RE, Borges-Neto S. Efficiency Comparison Between Tc-99m Tetrofosmin and Tc-99m Sestamibi Myocardial Perfusion Studies. Nucl Med Commun 23(3):203-8, 2002. e-Pub 2002. PMID: 11891477.
      55. Mast ST, Shaw LK, Ravizzini GC, Chabless M, Joski P, Coleman RE, Borges-Neto S. Incremental Prognostic Value of RNA Ejection Fraction Measurements During Pharmacologic Stress Testing: A Comparison with Clinical and Perfusion Variables. J Nucl Med 42(6):871-7, 2001. e-Pub 2001. PMID: 11390550.
      56. Ravizzini GC, Farnsworth SE, Pagnanelli RA, Borges-Neto S. Detection of a Large Substernal Goiter During Tc-99m Tetrofosmin Cardiac SPECT Imaging. J Nucl Cardiol 8(3):421-2, 2001. e-Pub 2001. PMID: 11391314.
      57. Ravizzini GC, Wagner M, Borges-Neto S. Positron Emission Tomography Detection of Metastatic Penile Squamous Cell Carcinoma. J Urol 165(5):1633-4, 2001. e-Pub 2001. PMID: 11342941.
      58. Almeida-Filho P, Ravizzini GC, Almeida C, Borges-Neto S. Whole-Body Tc-99m Sestamibi Scintigraphy in the Follow-up of Differentiated Thyroid Carcinoma. Clin Nucl Med 25(6):443-6, 2000. e-Pub 2000. PMID: 10836693.
      59. Borges-Neto S, Javaid A, Shaw LK, Kong DF, Hanson MW, Pagnanelli RA, Ravizzini GC, Coleman RE. Post-stress Measurements of Left Ventricular Function with Gated Perfusion SPECT: Comparison with Resting Measurements by Using a Same-day Perfusion-Function Protocol. Radiology 215(2):529-33, 2000. e-Pub 2000. PMID: 10796936.
      60. Osuagwuh AI, Taiwo BB, Ngere LO. Crossbreeding in tropical sheep: incidence of dystocia and parturition losses. Trop Anim Health Prod 12(2):85-9, 1980. e-Pub 1980. PMID: 7414702.

      Invited Articles

      1. Mast ST, Ravizzini GC, Borges-Neto S. Acute Myocardial Perfusion Imaging in the Evaluation of Emergency Department Patients with Chest Pain. Applied Radiology 29(11):33-40, 2000. e-Pub 2000.

      Review Articles

      1. Bitar, RD, Zurita, P, Martiniova, L, Zurita-Saavedra, A, Ravizzini, G. Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure. Cancers 17(10), 2025. e-Pub 2025. PMID: 40427220.
      2. Abusalem M, Martiniova L, Soebianto S, DePalatis L, Ravizzini G. Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy. Cancers (Basel) 15(18), 2023. e-Pub 2023. PMID: 37760506.

      Other Articles

      1. Jani, AB, Ravizzini, G, Gartrell, BA, Siegel, BA, Twardowski, P, Saltzstein, D, Fleming, MT, Chau, A, Davis, P, Chapin, BF, Schuster, DM Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men with Suspected Prostate Cancer Recurrence. Journal of Urology 210(3):411-412, 2023. PMID: 37350185.

      Abstracts

      1. Kairemo K, Ravizzini GC, Macapinlac HA, Subbiah V. An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3′-deoxy-3′[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma. Diagnostics, 2017. e-Pub 2017.
      2. Meirelles GS, Ravizzini G, Schoder H, Gonen M, Morris M, Scher H, Larson S. Prognostic Value of FDG PET in Patients with Bone Metastases from Castrate-resistant Prostate Cancer. J Nucl Med, 2006. e-Pub 2006.
      3. Ravizzini G, Pryma DA, Strauss HW. Coronary Calcification Adds Prognostic Information to Myocardial Perfusion Imaging in Oncological Patients Undergoing Major Surgical Procedures. J Nucl Med, 2005. e-Pub 2005.
      4. Nanni C, Ravizzini G, Fanti S, Nguyen M, Bannister C, Castellucci P, Farsad M, Halkar R. 18F-FDG PET-CT Imaging in Pediatric Extracranial Neoplastic Diseases: Issues and Pitfalls. J Nucl Med, 2004. e-Pub 2004.
      5. Srivatsa S, Ravizzini GC, Galt JR, Halkar RK. Preliminary Results of a Prospective Comparison Between Thyrogen Stimulated TcO4 and Nal-131 Whole Body Scan for the Follow-up of Differentiated Thyroid Carcinoma. J Nucl Med, 2004. e-Pub 2004.
      6. Nguyen M, Ravizzini GC, Schuster D, Halkar RK. Does SPECT/CT Imaging Provide Additional Benefits over Traditional Planar and SPECT Imaging of Hyperfunctioning Parathyroids?. Radiology, 2003. e-Pub 2003.
      7. Ravizzini GC, Pagnanelli RA, Coleman RE, Borges-Neto S. Cost Analysis Comparison Between 99mTc-Tetrofosmin and 99mTc-Sestamibi Myocardial Perfusion Imaging Protocols. Radiology, 2001. e-Pub 2001.
      8. Borges-Neto S, Hardenbergh P, Ravizzini GC, Mast S, Coleman RE. Combined Assessment of Myocardial Perfusion and Left Ventricular Function for the Evaluation of Patients with Breast Cancer Undergoing Radiation Therapy. J Am Coll Cardiol, 2000. e-Pub 2000.
      9. Borges-Neto S, Hanson MW, Ravizzini GC, Wong TZ, Hagge RJ, Shaw LK, Coleman RE. Efficiency Comparison Between Tc-99m Tetrofosmin and Tc99m Sestamibi Myocardial Perfusion Studies. J Nucl Med, 2000. e-Pub 2000.
      10. Borges-Neto S, Ravizzini GC, Mast S, Coleman RE. Prediction of Outcomes in Patients with Suspected or Known Coronary Artery Disease (CAD) by Tc-99m Tetrofosmin Stress Myocardial Perfusion Imaging Studies. J Am Coll Cardiol, 2000. e-Pub 2000.
      11. Borges-Neto S, Shaw LK, Ravizzini G, Coleman RE. Prediction of Death and MI by Myocardial Perfusion and Function Assessment after Revascularization: Does Perfusion Imaging adds Prognostic Information to Ejection Fraction?. Circulation, 1999. e-Pub 1999.
      12. Borges-Neto S, Shaw L, Ravizzini G, ColemanRE. Prediction of Cardiovascular Death by Combined Radionuclide Perfusion and Function: Does Gender Differences are Present?. J Nucl Med, 1999. e-Pub 1999.
      13. Chism CB, Somcio R, Chasen BA, Ravizzini GC. Increased 18F-FDG Uptake Associated with Gastric Banding Surgical Mesh on PET/CT. Clin Nuc Med. PMID: 26825203.

      Book Chapters

      1. De Palatis, L, Martiniova, L, de Almeida Graff, T, Ravizzini, G. Applications of PSMA-PET in tumors other than prostate cancer, 532-548, 2022.
      2. Gupta MP, Chuang HH, Ravizzini GC. Pitfalls and Classic Signs of the Abdomen and Pelvis. In: Sevtion 12: PET/CT, Specialty Imaging. First. Elsevier, 2015.
      3. Brandon DC, Thomas AJ, Ravizzini GC. Chapter 2: Introduction to Nuclear Medicine. In: Introduction to Diagnostic Radiology. First Edition. McGraw-Hill Professional, 2014.
      4. Ravizzini GC, Iver R, Macapinlac H. Imaging of Colon Cancer. In: Nuclear Oncology. Wolter Kluwer Health, 2014.
      5. Turkbey B, Ravizzini G, Choyke PL. Chapter 13: In Vivo Imaging of Tumor Angiogenesis. In: Tumor Angiogenesis. From Molecular Mechanisms to Targeted Therapy. Wiley-VCH, 2010.
      6. Turkbey B, Ravizzini G, Choyke PL, Kobayashi H. Chapter 7: Lymphangiogenesis and Imaging of the Lymphatics in Cancer. In: Volume 13 of Cancer Metastasis-Biology and Treatment. Springer, 2009.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top